Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:INVESTORS ARENT BUYING IT YET

[CancerSlayer]

Bigkahuna57 wrote: @CS, please correct me if I don't recall these details as has been stated. 

1) The Keytruda/BCG compound requires many more installations/visits.
2) Keytruda has possible debilitatiing side effects.  Do patients get followup after treatment to see if they are reactive to these side effects? Is that a treatment data point ever recorded so those reactions are tracked?  Or would that only happen if the UroOncologist reports the adverse reactions after treatment?
3) Is the BCG/Keytruda compound permitted to treat early onset NMIBC, instead of our requirement to meet BCG resistant NMIBC patients? My point is we're only permitted to treat patients with the worst conditions or "last resort" prior to bladder removal.  If true how could our trail not be granted BTD/AA/FDA approval?

I love the science but know nothing of the medical treatment and statistics elements.

Thank you to anyone that can provide any details.  I would think this would lead to stong conclusions as to whether FDA/HC would consider an early AA and final approval.

Thank you.

Good Luck to All.
Regards, BK

It is/should be routine to have follow-up after treatments to monitor/document/report both treatment response & side effects, whether it be in a clinical trial or in practice.

Keytruda & other combo therapies are indicated for the treatment of high-risk bcg-unresponsive NMIBC (CIS), which is a more advanced stage of NMIBC.  However, this advanced stage of NMIBC would be considered an earlier stage of bladder cancer as a whole, which includes muscle-invasive bladder cancer (MIBC) & more advanced stages....I'm not a urologist or oncologist, but that is my understanding.

Keep in mind, there are many treatments (including combo treatments) that are currently being used off-label (common in the oncology field) based on retrospective studies & experience.  I see a future where our anti-cancer therapy could be effectively combined with BCG or even replace BCG if proven effective in appropriate clinical studies.

The fact that there is such great need to find less costly & more patient-friendly options for this highly unmet condition, I also see no other path but approval from a scientific standpoint.